A phase I/II safety, tolerability and 'proof of concept' study of radiotherapy, cetuximab, and intratumoral injections of TNFerade [tumour necrosis factor-alpha gene therapy] biologic (AdGVEGR.TNF.11D) for elderly or frail patients with head and neck cancer
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2012
At a glance
- Drugs Golnerminogene pradenovec (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Adverse reactions; Proof of concept
- Acronyms TNF-ELF
- Sponsors GenVec
- 22 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 31 Jan 2007 New trial record.